Literature DB >> 25172534

Subcutaneous bortezomib for treatment of TEMPI syndrome.

Sina Jasim1, Gibran Mahmud2, Bahar Bastani3, Mark Fesler2.   

Abstract

Entities:  

Keywords:  Monoclonal gammopathy; Neuropathy; Perinephric cysts; Polycythemia; Telangiectasia

Mesh：

Substances：

Year:  2014        PMID： 25172534     DOI： 10.1016/j.clml.2014.07.004

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  6 in total

1.  Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation.

Authors:  S S Kenderian; F G Rosado; D B Sykes; J D Hoyer; M Q Lacy
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

Review 2.  TEMPI Syndrome: Update on Clinical Features, Management, and Pathogenesis.

Authors:  Jian Xu; Wenqi Liu; Fengjuan Fan; Bo Zhang; Fei Zhao; Yu Hu; Chunyan Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-19       Impact factor: 6.055

3.  Polycythaemia: an unusual presentation of multiple myeloma.

Authors:  Elaine J Hutchison; Josephine A Taverna; Qi Yu; Andrew M Yeager
Journal:  BMJ Case Rep       Date:  2016-09-20

4.  Ocular involvement in TEMPI syndrome.

Authors:  Jo-Hsuan Wu; Narine Viruni; Justin Chun; Satish Shanbhag; T Y Alvin Liu
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-10

Review 5.  Cutaneous manifestations of monoclonal gammopathy.

Authors:  Jean-Sebastien Claveau; David A Wetter; Shaji Kumar
Journal:  Blood Cancer J       Date:  2022-04-11       Impact factor: 11.037

6.  Case Report: TEMPI syndrome: Report of three cases and treatment follow-up.

Authors:  Zhuo-Fan Xu; Jing Ruan; Long Chang; Sijin Wu; Jinkai Lin; Wei Wang; XinXin Cao; Lu Zhang; Jian Li; Daobin Zhou; Wei Zhang
Journal:  Front Oncol       Date:  2022-08-03       Impact factor: 5.738
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.